| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 281.150.119 $ | +280.979.908 $ | +430.870,5 % | 6 | 170.211 $ | +170.211 $ | 6 | |||||
| Oruka Therapeutics, Inc. | ORKA | → 0 | Neutral | 76.795.672 $ | +76.748.618 $ | +163.107,5 % | 1 | 47.054 $ | +47.054 $ | 1 | |
| Spyre Therapeutics, Inc. | SYRE | → 0 | Neutral | 73.452.292 $ | +73.404.586 $ | +153.868,7 % | 1 | 47.706 $ | +47.706 $ | 1 | |
| Damora Therapeutics, Inc. | GLTO | → 0 | 52.977.750 $ | +52.974.978 $ | +1.911.074,2 % | 1 | 2.772 $ | +2.772 $ | 1 | ||
| Apogee Therapeutics, Inc. | APGE | → 0 | Schwach | 49.120.854 $ | +49.076.804 $ | +111.411,6 % | 1 | 44.050 $ | +44.050 $ | 1 | |
| Jade Biosciences, Inc. | JBIO | → 0 | Schwach | 22.167.388 $ | +22.143.043 $ | +90.955,2 % | 1 | 24.345 $ | +24.345 $ | 1 | |
| CRESCENT BIOPHARMA, INC. | CBIO | → 0 | Neutral | 6.636.163 $ | +6.631.879 $ | +154.805,8 % | 1 | 4.284 $ | +4.284 $ | 1 | |
| 281.150.119 $ | +280.979.908 $ | +430.870,5 % | 6 | 170.211 $ | +170.211 $ | 6 | |||||